T
TransThera Sciences (Nanjing) Inc
HKEX:2617
TransThera Sciences (Nanjing) Inc
HKEX:2617
Price:
70.8
HKD
-0.84%
Market Closed
Market Cap:
HK$28.1B
Relative Value
There is not enough data to reliably calculate the relative value of TransThera Sciences (Nanjing) Inc.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
Not Available
T
Multiples Across Competitors
Competitors Multiples
TransThera Sciences (Nanjing) Inc Competitors
TransThera Sciences (Nanjing) Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
T
|
TransThera Sciences (Nanjing) Inc
HKEX:2617
|
28.1B HKD | 0 | -91 | -89.1 | -87.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
395.5B USD | 6.6 | 168.3 | 16.3 | 23.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
198.2B USD | 5.4 | 25.5 | 14.7 | 14.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
184.1B USD | 6.3 | 22.7 | 15.4 | 15.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.1B USD | 10.1 | 32.1 | 23.6 | 24.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80B USD | 5.6 | 17.8 | 13.2 | 15.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
78B AUD | 3.5 | 18.1 | 12.3 | 15.3 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.9B EUR | 14.2 | 33.3 | 56.8 | 58.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
